Robert Blakeburn, MD
Family Medicine · Clinton, OKNPI 1164419560
Payments from drug & device makers
Across 53 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$145
- AbbVie$141
- Novo Nordisk$137
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$95
- Viatris Specialty LLC$80
- Johnson & Johnson$76
- plus $455 from 14 others
What the payments were for
- Food & beverage$1,11098%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 1 | $145 |
| AbbVie | 7 | $141 |
| Novo Nordisk | 8 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $95 |
| Viatris Specialty LLC | 3 | $80 |
| Johnson & Johnson | 1 | $76 |
| Lilly USA, LLC | 3 | $65 |
| Bayer | 3 | $49 |
| Pfizer | 3 | $41 |
| Nevro Corp. | 2 | $41 |
| AstraZeneca | 2 | $35 |
| Exact Sciences | 2 | $35 |
| Amgen | 2 | $34 |
| Merck | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $28 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| Novartis | 1 | $18 |
| GSK | 1 | $18 |
| Eisai Inc. | 1 | $14 |
How this compares
$1,130 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $65,461 |
| JardianceEmpagliflozin | 69 | $48,695 |
| XareltoRivaroxaban | 51 | $37,234 |
| OzempicSemaglutide | 36 | $33,456 |
| TrulicityDulaglutide | 23 | $30,533 |
| FarxigaDapagliflozin Propanediol | 40 | $28,916 |
| TrintellixVortioxetine Hydrobromide | 32 | $22,924 |
| MounjaroTirzepatide | 16 | $19,569 |
| MyrbetriqMirabegron | 36 | $18,553 |
| JanuviaSitagliptin Phosphate | 19 | $15,027 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,005 |
| LinzessLinaclotide | 11 | $7,812 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,301 |
| TradjentaLinagliptin | 11 | $7,006 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $41 | $69,890104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $65 | $50,10239 claims |
| Johnson & JohnsonXarelto | $76 | $37,23451 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $35 | $36,21752 claims |
| Novo NordiskOzempic | $137 | $33,45636 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $28 | $22,92432 claims |
| MerckJanuvia | $29 | $15,02719 claims |
| GSKAnoro Ellipta, Breo Ellipta | $18 | $14,36325 claims |
| AbbVieLinzess | $141 | $7,81211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Clinton
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.